International Flavors & Fragrances (IFF) Q4 2024 earnings summary

Executive summary

• Achieved $11.5 billion in 2024 sales, up 6% currency-neutral, with broad-based volume growth and improved profitability.

• Adjusted Operating EBITDA grew 16% to over $2.2 billion, driven by operational discipline, productivity initiatives, and innovation.

• Strategic focus on R&D, commercial capabilities, and CapEx in high-growth, high-margin segments: Health and Biosciences, Taste, and Scent.

• Completed Cosmetics Ingredients divestiture and announced sale of Pharma Solutions as part of portfolio optimization.

• Board refreshed with new members and chair; leadership changes included new CFO and internal promotions.

Financial highlights

• FY 2024 sales reached $11.5B; comparable currency-neutral sales increased 6% year-over-year.

• Adjusted operating EBITDA was $2.2B, up 16% on a comparable basis.

• Q4 2024 revenue was $2.77B, up 6% currency-neutral; adjusted operating EBITDA grew 5% to $471M.

• Free cash flow for 2024 was $606M; $514M distributed in dividends.

• Net debt-to-credit-adjusted EBITDA improved to 3.8x from 4.5x year-over-year.

Outlook and guidance

• 2025 sales expected at $10.6–$10.9 billion, 1–4% currency-neutral growth, with 5–10% EBITDA growth.

• Guidance includes six months of Pharma Solutions; divestiture expected by June 30, 2025.

• CapEx to rise to ~6% of sales, with half for maintenance and the rest for growth and digital transformation.

• Free cash flow for 2025 projected at $500 million, or $850 million excluding Pharma divestiture taxes.

• FX and divestitures expected to have a combined adverse impact of ~9–10% on sales and EBITDA growth.